Physician profile
Sydney Shaffer
NPI 1063099687
$1,881.74
in general payments reported to CMS, 2019-2025
13 companies · $658 in 2025
The $658 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $657 · 2023: $236 · 2024: $330 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100 · Consulting Fee: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.20 |
| Consulting Fee | $124.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $602.70 | 2022-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $239.99 | 2022 | |
| Amgen INC. | $218.99 | 2024-2025 | Uplizna |
| Genentech USA, INC. | $146.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2022 | |
| Octapharma USA, INC. | $124.62 | 2025 | Octagam Immune Globulin (Human) |
| Tg Therapeutics, INC. | $123.99 | 2024 | |
| Genzyme Corporation | $100.44 | 2023 | |
| Biogen, INC. | $61.34 | 2022-2023 | |
| Abbvie INC. | $50.95 | 2025 | |
| Livanova USA, INC. | $44.47 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Abbott Laboratories | $22.03 | 2025 | Infinity |
| Neurelis, INC. | $21.18 | 2025 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.